BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...

Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization ...

Mineralys Therapeutics is working on a treatment for patients with uncontrolled hypertension. Mineralys Therapeutics' stock price skyrocketed Monday morning after the Main Line biopharmaceutical ...

Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.29. The stock has a market cap of $712.65 million, a P/E ratio of -3.93 and a beta of 1.50.

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10 ...